Amgen, Servier strike deal to sell, develop heart drugs

Amgen and Servier said they reached an agreement to potentially market each other’s heart drugs and co-develop another experimental drug.

Amgen and Servier said they reached an agreement to potentially market each other’s heart drugs and co-develop another experimental drug.

Amgen will pay $50 million plus future milestone and royalty payments for the US sales rights to Servier’s ivabradine for...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category